IONS Stock - Ionis Pharmaceuticals, Inc.
Unlock GoAI Insights for IONS
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $705.14M | $787.65M | $587.37M | $810.46M | $729.26M |
| Gross Profit | $693.92M | $778.51M | $573.25M | $799.61M | $717.32M |
| Gross Margin | 98.4% | 98.8% | 97.6% | 98.7% | 98.4% |
| Operating Income | $-475,081,000 | $-353,730,000 | $-410,191,000 | $-30,186,000 | $-172,082,000 |
| Net Income | $-453,897,000 | $-366,286,000 | $-269,722,000 | $-28,597,000 | $-444,263,000 |
| Net Margin | -64.4% | -46.5% | -45.9% | -3.5% | -60.9% |
| EPS | $-3.04 | $-2.56 | $-1.90 | $-0.20 | $-3.18 |
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of TTR amyloidosis; Olezarsen for patients with severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Tofersen to inhibit the production of superoxide dismutase 1. In addition, the company develops medicines for metabolic diseases, infectious diseases, renal diseases, ophthalmic diseases, and cancer. It has a strategic collaboration with Biogen Inc.; and collaboration and license agreement with AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis AG, Roche, Janssen Biotech, Inc., and Flamingo Therapeutics, Inc. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California.
Visit WebsiteEarnings History & Surprises
IONSEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 28, 2026 | — | — | — | — |
Q1 2026 | Feb 18, 2026 | $-1.23 | — | — | — |
Q4 2025 | Oct 28, 2025 | — | $-0.80 | — | — |
Q3 2025 | Jul 30, 2025 | — | $0.68 | — | — |
Q2 2025 | Apr 30, 2025 | $-1.11 | $-0.75 | +32.4% | ✓ BEAT |
Q1 2025 | Feb 19, 2025 | $-1.09 | $-0.66 | +39.4% | ✓ BEAT |
Q4 2024 | Nov 6, 2024 | $-1.16 | $-0.95 | +18.1% | ✓ BEAT |
Q3 2024 | Aug 1, 2024 | $-0.92 | $-0.45 | +51.1% | ✓ BEAT |
Q1 2024 | Feb 21, 2024 | $-0.83 | $-0.06 | +92.8% | ✓ BEAT |
Q1 2024 | Jan 10, 2024 | $-0.83 | $-0.06 | +92.8% | ✓ BEAT |
Q4 2023 | Nov 2, 2023 | $-1.04 | $-1.03 | +1.0% | ✓ BEAT |
Q3 2023 | Aug 9, 2023 | $-0.90 | $-0.60 | +33.3% | ✓ BEAT |
Q2 2023 | May 3, 2023 | $-0.91 | $-0.87 | +4.4% | ✓ BEAT |
Q1 2023 | Feb 22, 2023 | $-1.06 | $-0.37 | +65.1% | ✓ BEAT |
Q4 2022 | Nov 9, 2022 | $-0.74 | $-0.33 | +55.4% | ✓ BEAT |
Q3 2022 | Aug 9, 2022 | $-0.62 | $-0.74 | -19.4% | ✗ MISS |
Q2 2022 | May 4, 2022 | $-0.71 | $-0.46 | +35.2% | ✓ BEAT |
Q1 2022 | Feb 24, 2022 | $0.28 | $1.41 | +403.6% | ✓ BEAT |
Q4 2021 | Nov 3, 2021 | $-0.53 | $-0.58 | -9.4% | ✗ MISS |
Q3 2021 | Aug 4, 2021 | $-0.60 | $-0.57 | +5.0% | ✓ BEAT |
Latest News
Frequently Asked Questions about IONS
What is IONS's current stock price?
What is the analyst price target for IONS?
What sector is Ionis Pharmaceuticals, Inc. in?
What is IONS's market cap?
Does IONS pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to IONS for comparison